Close Menu
Home » Epic Sciences, Genomic Health Receive Favorable Draft LCD for Prostate Cancer AR-V7 Test

Epic Sciences, Genomic Health Receive Favorable Draft LCD for Prostate Cancer AR-V7 Test

Mar 30, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Epic Sciences and Genomic Health said today that Medicare contractor Palmetto GBA has issued a draft local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test.

The companies said that if finalized, the LCD would extend coverage of the test to 25,000 Medicare patients with advanced prostate cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Unexpected Close

GenomeWeb reports that Veritas Genetics is suspending its US operations.

Sweet Assembly

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Oh, You're Aging Well

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

Science Papers Describe MicroRNA Targeting Efficiency, Approach for Single-Cell High-Throughput Chemical Screens

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. Veritas Genetics Halts US Operations, Lays Off More Than 30

  2. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  3. Hologic Vaginitis Tests Offer Improvements Over Gold Standard Methods

    Premium

  4. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

  5. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.